File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.

TitleSARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.
Authors
Jaume, MYip, MSKam, YWCheung, CYKien, FRoberts, ALi, PHDutry, IEscriou, NDaeron, MBruzzone, RSubbarao, KPeiris, JSNal, BAltmeyer, R
Issue Date2012
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy Of Medicine, 2012, v. 18 Suppl 2, p. 31-36 How to Cite?
Abstract1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).
Persistent Identifierhttp://hdl.handle.net/10722/179836
ISSN
1024-2708
2021 Impact Factor: 1.256
2020 SCImago Journal Rankings: 0.357

 

DC FieldValueLanguage
dc.contributor.authorJaume, Men_US
dc.contributor.authorYip, MSen_US
dc.contributor.authorKam, YWen_US
dc.contributor.authorCheung, CYen_US
dc.contributor.authorKien, Fen_US
dc.contributor.authorRoberts, Aen_US
dc.contributor.authorLi, PHen_US
dc.contributor.authorDutry, Ien_US
dc.contributor.authorEscriou, Nen_US
dc.contributor.authorDaeron, Men_US
dc.contributor.authorBruzzone, Ren_US
dc.contributor.authorSubbarao, Ken_US
dc.contributor.authorPeiris, JSen_US
dc.contributor.authorNal, Ben_US
dc.contributor.authorAltmeyer, Ren_US
dc.date.accessioned2012-12-19T10:05:19Z-
dc.date.available2012-12-19T10:05:19Z-
dc.date.issued2012en_US
dc.identifier.citationHong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy Of Medicine, 2012, v. 18 Suppl 2, p. 31-36en_US
dc.identifier.issn1024-2708en_US
dc.identifier.urihttp://hdl.handle.net/10722/179836-
dc.description.abstract1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).en_US
dc.languageengen_US
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_US
dc.relation.ispartofHong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicineen_US
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Neutralizing - Metabolismen_US
dc.subject.meshAntibodies, Viral - Metabolismen_US
dc.subject.meshAntibody-Dependent Enhancementen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshCysteine Proteases - Metabolismen_US
dc.subject.meshHumansen_US
dc.subject.meshHydrogen-Ion Concentrationen_US
dc.subject.meshMembrane Glycoproteins - Immunologyen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Balb Cen_US
dc.subject.meshMonocytesen_US
dc.subject.meshPeptidyl-Dipeptidase A - Metabolismen_US
dc.subject.meshReceptors, Fc - Metabolismen_US
dc.subject.meshSars Virus - Immunology - Physiologyen_US
dc.subject.meshSevere Acute Respiratory Syndrome - Immunologyen_US
dc.subject.meshVaccinesen_US
dc.subject.meshViral Envelope Proteins - Immunologyen_US
dc.subject.meshVirus Internalizationen_US
dc.titleSARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.en_US
dc.typeArticleen_US
dc.identifier.emailBruzzone, R: bruzzone@hkucc.hku.hken_US
dc.identifier.emailPeiris, JS: malik@hkucc.hku.hken_US
dc.identifier.emailNal, B: bnal@hkucc.hku.hken_US
dc.identifier.emailJaume, M: breizh@hku.hk-
dc.identifier.emailCheung, CY: chungey@hkucc.hku.hk-
dc.identifier.emailKien, F: kien@hkucc.hku.hk-
dc.identifier.emailLi, PH: phli@hkucc.hku.hk-
dc.identifier.emailDutry, I: dutry@connect.hku.hk-
dc.identifier.authorityBruzzone, R=rp01442en_US
dc.identifier.authorityPeiris, JS=rp00410en_US
dc.identifier.authorityNal, B=rp00541en_US
dc.identifier.authorityCheung, CY=rp00404-
dc.description.naturepublished_or_final_versionen_US
dc.identifier.pmid22311359-
dc.identifier.scopuseid_2-s2.0-84861557831en_US
dc.identifier.hkuros213654-
dc.identifier.volume18 Suppl 2en_US
dc.identifier.spage31en_US
dc.identifier.epage36en_US
dc.publisher.placeHong Kongen_US
dc.identifier.f1000735599597-
dc.identifier.scopusauthoridJaume, M=6603007958en_US
dc.identifier.scopusauthoridYip, MS=54397823800en_US
dc.identifier.scopusauthoridKam, YW=15122219300en_US
dc.identifier.scopusauthoridCheung, CY=55232701000en_US
dc.identifier.scopusauthoridKien, F=7004231633en_US
dc.identifier.scopusauthoridRoberts, A=7404498719en_US
dc.identifier.scopusauthoridLi, PH=55232853900en_US
dc.identifier.scopusauthoridDutry, I=54396851000en_US
dc.identifier.scopusauthoridEscriou, N=6603606703en_US
dc.identifier.scopusauthoridDaeron, M=7005773227en_US
dc.identifier.scopusauthoridBruzzone, R=7006793327en_US
dc.identifier.scopusauthoridSubbarao, K=7102213212en_US
dc.identifier.scopusauthoridPeiris, JS=7005486823en_US
dc.identifier.scopusauthoridNal, B=6506672380en_US
dc.identifier.scopusauthoridAltmeyer, R=7003677186en_US
dc.identifier.issnl1024-2708-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats